相似文献
1
Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00449-17. Print 2017 Jul.
2
Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
Int J Antimicrob Agents. 2018 Apr;51(4):629-635. doi: 10.1016/j.ijantimicag.2018.01.016. Epub 2018 Feb 2.
3
Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
Int J Antimicrob Agents. 2017 Jun;49(6):770-773. doi: 10.1016/j.ijantimicag.2017.01.018. Epub 2017 Apr 4.
4
Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam.
Int J Antimicrob Agents. 2019 Apr;53(4):520-524. doi: 10.1016/j.ijantimicag.2018.11.015. Epub 2018 Nov 22.
5
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783.
6
Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Infections.
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02313-19.
7
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.
Clin Infect Dis. 2016 Dec 15;63(12):1615-1618. doi: 10.1093/cid/ciw636. Epub 2016 Sep 13.
8
Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Clin Ther. 2016 Mar;38(3):431-44. doi: 10.1016/j.clinthera.2016.01.018. Epub 2016 Mar 2.
9
Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae.
J Antimicrob Chemother. 2018 Nov 1;73(11):3170-3175. doi: 10.1093/jac/dky295.
10
Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae.
BMC Infect Dis. 2019 Sep 4;19(1):772. doi: 10.1186/s12879-019-4409-1.
引用本文的文献
1
Ceftazidime-Avibactam in Critically Ill Patients: A Multicenter Observational Study.
Antibiotics (Basel). 2025 Aug 5;14(8):797. doi: 10.3390/antibiotics14080797.
2
Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review.
JAC Antimicrob Resist. 2025 Jun 19;7(3):dlaf096. doi: 10.1093/jacamr/dlaf096. eCollection 2025 Jun.
3
The efficacy of polymyxin B in treating stroke-associated pneumonia with carbapenem-resistant Gram-negative bacteria infections: a multicenter real-world study using propensity score matching.
Front Pharmacol. 2025 Mar 20;16:1413563. doi: 10.3389/fphar.2025.1413563. eCollection 2025.
4
Are New β-Lactam/β-Lactamase Inhibitor Combinations Promising Against Carbapenem-Resistant Isolates?
Pathogens. 2025 Feb 24;14(3):220. doi: 10.3390/pathogens14030220.
5
Mortality-related risk factors of carbapenem-resistant Enterobacteriaceae infection with focus on antimicrobial regimens optimization: a real-world retrospective study in China.
BMC Infect Dis. 2025 Jan 23;25(1):110. doi: 10.1186/s12879-025-10454-z.
6
Efficiency of combination therapy versus monotherapy for the treatment of infections due to carbapenem-resistant Gram-negative bacteria: a systematic review and meta-analysis.
Syst Rev. 2024 Dec 19;13(1):309. doi: 10.1186/s13643-024-02695-x.
7
A systematic review of efficacy and safety of newer drugs approved from 2016 to 2023 for the treatment of complicated urinary tract infections.
Ann Med. 2024 Dec;56(1):2403724. doi: 10.1080/07853890.2024.2403724. Epub 2024 Nov 12.
8
Ceftazidime-Avibactam as a Salvage Treatment for Severely Infected Immunosuppressed Children.
Drug Des Devel Ther. 2024 Jul 30;18:3399-3413. doi: 10.2147/DDDT.S467967. eCollection 2024.
9
Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use.
World J Emerg Surg. 2024 Jun 8;19(1):23. doi: 10.1186/s13017-024-00551-w.
10
Ceftazidime-Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta-analysis.
Infect Dis Ther. 2024 Jul;13(7):1639-1664. doi: 10.1007/s40121-024-00999-y. Epub 2024 May 31.
本文引用的文献
1
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.
Clin Infect Dis. 2016 Dec 15;63(12):1615-1618. doi: 10.1093/cid/ciw636. Epub 2016 Sep 13.
2
Sepsis: pathophysiology and clinical management.
BMJ. 2016 May 23;353:i1585. doi: 10.1136/bmj.i1585.
3
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.
Clin Infect Dis. 2016 Jun 1;62(11):1380-1389. doi: 10.1093/cid/ciw133. Epub 2016 Mar 8.
4
Deaths attributable to carbapenem-resistant Enterobacteriaceae infections.
Emerg Infect Dis. 2014 Jul;20(7):1170-5. doi: 10.3201/eid2007.121004.
5
Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.
Core Evid. 2014 Jan 24;9:13-25. doi: 10.2147/CE.S40698. eCollection 2014.
6
Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial.
J Antimicrob Chemother. 2013 May;68(5):1183-92. doi: 10.1093/jac/dks523. Epub 2013 Feb 7.
7
Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes.
Diagn Microbiol Infect Dis. 2013 Feb;75(2):115-20. doi: 10.1016/j.diagmicrobio.2012.11.009. Epub 2013 Jan 3.
8
Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.
Antimicrob Agents Chemother. 2012 Apr;56(4):2108-13. doi: 10.1128/AAC.06268-11. Epub 2012 Jan 17.
9
International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections.
Ann Intern Med. 2004 Jan 6;140(1):26-32. doi: 10.7326/0003-4819-140-1-200401060-00008.
10
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8.
Zotero 插件